Sandoz Agrees To Shelve Plans For Generic Zetia

Law360, New York (September 9, 2013, 7:24 PM EDT) -- Generic-drug maker Sandoz Inc. on Monday agreed not to make, sell or distribute a version of Merck & Co. Inc.'s anti-cholesterol drug Zetia until 2017, putting to rest Merck's patent infringement suit.

Sandoz and its affiliates Sandoz AG, Sandoz International GmbH, Eon Labs Inc., Oriel Therapeutics Inc., Falcon Pharmaceuticals Inc., Lek Pharmaceuticals d.d. and Fougera Pharmaceuticals Inc. are all subject to the settlement, which was approved by U.S. District Judge Jose Linares.

"Except as and to the extent permitted by the settlement agreement, Sandoz, including any of its successors and assigns, is enjoined until April 25, 2017, from making, having made,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!